Anthony A Portale1, Myles Wolf, Harald Jüppner, Shari Messinger, Juhi Kumar, Katherine Wesseling-Perry, George J Schwartz, Susan L Furth, Bradley A Warady, Isidro B Salusky. 1. Department of Pediatrics, University of California, San Francisco, California;, †Department of Medicine and, §Department of Epidemiology and Public Health, University of Miami Miller School of Medicine, Miami, Florida;, ‡Department of Pediatrics, Harvard Medical School, Boston, Massachusetts;, ‖Department of Pediatrics, Weill Cornell Medical College, New York, New York;, ¶Department of Pediatrics, University of California, Los Angeles, California;, *Department of Pediatrics, University of Rochester School of Medicine, Rochester, New York;, ††Department of Pediatrics, University of Pennsylvania, Philadelphia, Pennsylvania, ‡‡Department of Pediatrics, University of Missouri-Kansas City School of Medicine, Kansas City, Missouri.
Abstract
BACKGROUND AND OBJECTIVES: In children with CKD, information is limited regarding the prevalence and determinants of fibroblast growth factor 23 excess and 1,25-dihyroxyvitamin D deficiency across the spectrum of predialysis CKD. This study characterized circulating concentrations of fibroblast growth factor 23 and 1,25-dihyroxyvitamin D, and investigated their interrelationships and associations with GFR and secondary hyperparathyroidism in children with CKD who were enrolled in the Chronic Kidney Disease in Children observational cohort study. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Plasma fibroblast growth factor 23 concentrations and determinants of mineral metabolism were measured in 464 children ages 1-16 years with predialysis CKD. GFR was measured by plasma disappearance of iohexol in 70% of participants and estimated by the Chronic Kidney Disease in Children estimating equation using serum creatinine and cystatin C concentrations in the remainder of the participants. Participants were grouped according to CKD stage and by 10-ml/min categories of GFR. RESULTS: Median GFR for the cohort was 45 ml/min per 1.73 m(2) (interquartile range=33-57; range=15-109). Plasma fibroblast growth factor 23 concentration was above the normal range in 67% of participants (with higher levels observed among participants with lower GFR) before higher levels of serum parathyroid hormone and phosphorus were observed. Plasma fibroblast growth factor 23 levels were 34% higher in participants with glomerular disease than in participants with nonglomerular disease, despite similar GFR. Serum phosphorus levels, adjusted for age, were significantly lower at GFR of 60-69 ml/min per 1.73 m(2) than higher GFR, but thereafter they became higher in parallel with fibroblast growth factor 23 as GFR declined. Serum 1,25-dihyroxyvitamin D concentrations were lower in those participants with low GFR values, high fibroblast growth factor 23 levels, 25-hydroxyvitamin D deficiency, and proteinuria. Secondary hyperparathyroidism was present in 55% of participants with GFR<50 ml/min per 1.73 m(2). CONCLUSION: In children with predialysis CKD, high plasma fibroblast growth factor 23 is the earliest detectable abnormality in mineral metabolism, and levels are highest in glomerular diseases.
BACKGROUND AND OBJECTIVES: In children with CKD, information is limited regarding the prevalence and determinants of fibroblast growth factor 23 excess and 1,25-dihyroxyvitamin D deficiency across the spectrum of predialysis CKD. This study characterized circulating concentrations of fibroblast growth factor 23 and 1,25-dihyroxyvitamin D, and investigated their interrelationships and associations with GFR and secondary hyperparathyroidism in children with CKD who were enrolled in the Chronic Kidney Disease in Children observational cohort study. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Plasma fibroblast growth factor 23 concentrations and determinants of mineral metabolism were measured in 464 children ages 1-16 years with predialysis CKD. GFR was measured by plasma disappearance of iohexol in 70% of participants and estimated by the Chronic Kidney Disease in Children estimating equation using serum creatinine and cystatin C concentrations in the remainder of the participants. Participants were grouped according to CKD stage and by 10-ml/min categories of GFR. RESULTS: Median GFR for the cohort was 45 ml/min per 1.73 m(2) (interquartile range=33-57; range=15-109). Plasma fibroblast growth factor 23 concentration was above the normal range in 67% of participants (with higher levels observed among participants with lower GFR) before higher levels of serum parathyroid hormone and phosphorus were observed. Plasma fibroblast growth factor 23 levels were 34% higher in participants with glomerular disease than in participants with nonglomerular disease, despite similar GFR. Serum phosphorus levels, adjusted for age, were significantly lower at GFR of 60-69 ml/min per 1.73 m(2) than higher GFR, but thereafter they became higher in parallel with fibroblast growth factor 23 as GFR declined. Serum 1,25-dihyroxyvitamin D concentrations were lower in those participants with low GFR values, high fibroblast growth factor 23 levels, 25-hydroxyvitamin D deficiency, and proteinuria. Secondary hyperparathyroidism was present in 55% of participants with GFR<50 ml/min per 1.73 m(2). CONCLUSION: In children with predialysis CKD, high plasma fibroblast growth factor 23 is the earliest detectable abnormality in mineral metabolism, and levels are highest in glomerular diseases.
Authors: Manish D Sinha; Charles Turner; R N Dalton; Pernille Rasmussen; Simon Waller; Caroline J Booth; David J Goldsmith Journal: Nephrol Dial Transplant Date: 2012-04-23 Impact factor: 5.992
Authors: Diana L Ersfeld; D Sudhaker Rao; Jean-Jacques Body; James L Sackrison; Andrew B Miller; Nayana Parikh; Tar Lisha Eskridge; Amy Polinske; Gregory T Olson; Gordon D MacFarlane Journal: Clin Biochem Date: 2004-10 Impact factor: 3.281
Authors: Rebecca L Ruebner; Derek Ng; Mark Mitsnefes; Bethany J Foster; Kevin Meyers; Bradley Warady; Susan L Furth Journal: Clin J Am Soc Nephrol Date: 2016-09-14 Impact factor: 8.237
Authors: Mark R Hanudel; Kristine Chua; Maxime Rappaport; Victoria Gabayan; Erika Valore; David Goltzman; Tomas Ganz; Elizabeta Nemeth; Isidro B Salusky Journal: Am J Physiol Renal Physiol Date: 2016-10-12
Authors: Anthony A Portale; Myles S Wolf; Shari Messinger; Farzana Perwad; Harald Jüppner; Bradley A Warady; Susan L Furth; Isidro B Salusky Journal: Clin J Am Soc Nephrol Date: 2016-08-25 Impact factor: 8.237